Compare MKTX & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MKTX | ICUI |
|---|---|---|
| Founded | 2000 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.0B |
| IPO Year | 2004 | 1995 |
| Metric | MKTX | ICUI |
|---|---|---|
| Price | $164.15 | $160.52 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 8 |
| Target Price | $158.00 | ★ $193.38 |
| AVG Volume (30 Days) | ★ 734.9K | 216.3K |
| Earning Date | 11-06-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.90% | N/A |
| EPS Growth | N/A | ★ 100.62 |
| EPS | ★ 4.13 | 1.96 |
| Revenue | $397,471,000.00 | ★ $2,231,262,000.00 |
| Revenue This Year | $5.71 | N/A |
| Revenue Next Year | $6.80 | $4.44 |
| P/E Ratio | ★ $39.76 | $80.19 |
| Revenue Growth | ★ 7.45 | N/A |
| 52 Week Low | $108.75 | $112.50 |
| 52 Week High | $195.97 | $192.85 |
| Indicator | MKTX | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 80.44 | 48.28 |
| Support Level | $163.18 | $152.02 |
| Resistance Level | $165.87 | $167.67 |
| Average True Range (ATR) | 0.34 | 4.26 |
| MACD | -0.51 | 0.56 |
| Stochastic Oscillator | 86.07 | 66.40 |
Founded in 2000, MarketAxess is a leading electronic fixed-income trading platform that connects broker/dealers and institutional investors. The company is primarily focused on credit based fixed income securities with its main trading products being US investment-grade and high-yield bonds, Eurobonds, and Emerging Market corporate debt. Recently the company has expanded more aggressively into Treasuries and municipal bonds with the acquisitions of LiquidityEdge and MuniBrokers in 2019 and 2021, respectively. The company also provides pre- and post-trade services with its acquisition of Regulatory Reporting Hub from Deutsche Börse Group in 2020 adding to its product offerings.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.